Tag: CD19

CAR T-cell therapy in MS: in its infancy but highly anticipated

Presented By
Prof. Frauke Zipp, Johannes Gutenberg University Mainz, Germany
Conference
ECTRIMS 2024
Type
Peer-reviewed article

18 November 2024 12:33

Long-term success for CD19 CAR T-cell therapy in CLL

Presented By
Dr Emily Liang, University of Washington, WA, USA
Trial
Phase 2
Conference
EBMT 2023
Type
Peer-reviewed article

15 June 2023 17:31

Next-generation cell therapies for cancer: CAR-NK cells

Presented By
Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA
Conference
EBMT 2023
Type
Peer-reviewed article

15 June 2023 17:20

CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL

Expert
Dr Matthew J. Frank, Stanford University School of Medicine, USA
Conference
ASH 2021
Type
News article

4 February 2022 11:30

High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma

Expert
Dr Sattva S. Neelapu, MD Anderson Cancer Center, Houston, USA
Trial
ZUMA-12
Conference
ASH 2021
Type
News article

4 February 2022 11:25

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert
Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA
Trial
Cohort study, RE-MIND2
Conference
ASH 2021
Type
News article

4 February 2022 11:08

Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma

Expert
Dr Manali Kamdar, University of Colorado Cancer Center, Denver, USA
Trial
Phase 3, TRANSFORM
Conference
ASH 2021
Type
News article

4 February 2022 10:28

Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma

Expert
Dr Emmanuel Bachy, Hospices Civils de Lyon, France
Trial
JULIET, ZUMA-1
Conference
ASH 2021
Type
News article

4 February 2022 10:15

Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma

Expert
Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA
Trial
Phase 3, ZUMA-7
Conference
ASH 2021
Type
News article

4 February 2022 10:10

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert
Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA
Trial
Phase 3, BELINDA
Conference
ASH 2021
Type
News article

4 February 2022 10:03

Improved QoL with axi-cel versus standard-of-care in R/R LBCL

Expert
Dr Mahmoud Elsawy, Dalhousie University, Halifax, USA
Trial
Phase 3, ZUMA-7
Conference
ASH 2021
Type
News article

4 February 2022 09:48

Long-term efficacy data: inebilizumab for NMOSD

Presented By
Prof. Bruce Cree, UCSF Multiple Sclerosis Center, CA, USA
Trial
Phase 3, N-MOmentum
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 15:31

CD58 aberrations limit durable responses to CD19 CAR T-cell therapy

Presented By
Dr Robbie Majzner, Stanford University, California, USA
Conference
ASH 2020
Type
Peer-reviewed article

18 February 2021 10:15

Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL

Presented By
Dr Caron Jacobson, Dana Farber Cancer Institute, Massachusetts, USA
Trial
Phase 2, ZUMA-5
Conference
ASH 2020
Type
Peer-reviewed article

18 February 2021 10:12

MRD assessment post-CAR-T predicts ALL allo-HSCT bridging

Expert
Dr Hui Wang, Hebei Yanda Ludaopei Hospital, China
Conference
EHA 2020
Type
Peer-reviewed article

9 September 2020 11:02

Off-the-shelf natural killer cells

Presented By
Dr Jode Goodridge, Fate Therapeutics, USA
Conference
ASH 2019
Type
Peer-reviewed article

5 March 2020 09:38
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com